Bethany Bustamante, MD

Gynecologic Oncology
Accepting new patients
Sees patients age 18 and up
LG Health Physicians Gynecologic Oncology
Make an appointmentCall 717-544-9400
Headshot of Bethany Bustamante, MD
Penn Medicine Provider

About me

  • Adjunct Assistant Professor of Obstetrics and Gynecology

My education and training

  • Medical School: Marshall University School of Medicine
  • Residency: White Memorial Medical Center
  • Fellowship: Northwell Health

Spoken languages

English
English

Reviews

Average Rating

168 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
April 2026
she took her time and made sure that all of my questions were answered.
Anonymous
April 2026
i've been with dr. bustamante for a long time. she was fantastic when i was really sick. i have a friend who started with same cancer as me. she went to different provider her cancer spread. i personally feel like dr bustamante was a big part of my success
Anonymous
April 2026
answered all of my questions l was well informed
Anonymous
March 2026
dr. bustamante is the best!

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Lancaster General Hospital: Has privileges to treat patients in the hospital.
Dr. Bustamante is a Penn Medicine Lancaster General Health physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Bustamante B, Sinha R, Rice B, Shan W, Goldberg GL, John V, Lin DI, Danziger N, Pavlick DC, Elvin JA, Frimer M Clinical implications of genomic loss of heterozygosity in endometrial carcinoma. , JCO Precis Oncol, 5:PO.20.00393: 2021

Bustamante B, DeVoti J, Papayannakos C, Mohd I, Lam F, Steinberg B, Bonagura V, Goldbergy GL Circulating immune cells of patients with cervical dysplasia and cancer do not show elevated baseline expression of COX2. Poster presentation, , American Association for Cancer Research, Annual Meeting: 2021

Sinha R, Bustamante B, Truskinovsky A, Shih K Yolk sac tumor of the endometrium in a post-menopausal woman: Case report and review of the literature. , Gynecol Oncol Rep, 36:10074: 2021

Bustamante B, Sinha R, John V, Goldberg GL, Frimer M Does Genomic Loss of Heterozygosity (gLOH) in Endometrial Carcinomas (EC) predict platinum sensitivity (PS)? Poster presentation, , Society of Gynecology Oncology, Annual Meeting on Women’s Cancer: 2021

Scanlon L, Nizam A, Bustamante B, Shih, KK, Shan W, dos Santos L, Frimer M, Menzin AW, Sakaris A, Whyte JS, Goldberg GL Utilization of vaginal brachytherapy in locally advanced cervical cancer. Poster presentation, , SGO 2020 Annual Meeting on Women’s Cancer: 2021

Sinha R, Bustamante B, Tahmasebi F, Goldberg GL Malignant Female Adnexal Tumor of Probable Wolffian Origin (FATWO): A case report and review for the literature. , Gynecol Oncol Rep, 36:100726: 2021

Seay K, Akanbi T, Bustamante B, Chaudhary S, Goldberg GL Mesonephric-like adenocarcinoma of the ovary with co-existent endometriosis: A case report and review of the literature. , Gynecol Oncol Rep, 34:100657: 2020

Seay K, Bustamante B, Khutti S, Frimer M A case of non-HPV related primary endometrioid adenocarcinoma of the cervix. , Gynecol Oncol Rep, 32:10057: 2020

Nizam A, Bustamante B, Shih, KK, Shan W, dos Santos L, Frimer M, Menzin AW, Sakaris A, Whyte JS, Goldberg GL Neoadjuvant chemotherapy for stage III ovarian cancer: a single-institution experience. Poster presentation, , SGO 2020 Annual Meeting on Women’s Cancer: 2020

Nelson D, Nizam A, Bustamante B, Shih KK, Shan W, dos Santos L, Frimer M, Menzin AW, Sakaris A, Whyte JW, Goldberg GL What is the clinical significance of grade 2 histology in women with stage IA endometrial cancer? Poster presentation, , SGO 2020 Annual Meeting on Women’s Cancer: 2020